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Abstract
BACKGROUND
Autoimmune hepatitis (AIH) is a rare chronic inflammatory liver disease with a
high risk of progression to liver cirrhosis. The initial treatment for AIH usually
includes a steroid, with or without azathioprine. AIH can present at any age;
however, the most effective and safe induction treatment for AIH in the elderly
remains unclear.
AIM
To systematically review available data on both effectiveness and safety of AIH
treatments in elderly subjects.
METHODS
To identify studies on AIH induction treatment in elderly patients (≥ 60 years of
age), an electronic research was performed (PubMed, EMBASE and Cochrane
Library databases) until February 2019. Eligible studies were selected through
screening of titles and abstracts, followed by full-text critical evaluation. After
risk of bias assessment, data on study designs, interventions, and outcomes were
extracted and reviewed.
RESULTS
Among the 1736 retrieved papers, 15 studies were selected. Out of them, eight
studies were excluded because of a critical risk of bias. The remaining seven
studies included 789 patients and out of them 239 subjects were elders. First-line
treatment was a steroid either alone or in combination with azathioprine in most
patients (87.6%) and only one study investigated the effect of combined steroid
and mycophenolate mofetil therapy. Standard therapy was effective in inducing
remission in the elderly. Moreover, treatment failure and relapses occurred less
often in the elderly compared to younger people.
CONCLUSION
Treatment of AIH is challenging in elderly patients. This systematic review
confirms the efficacy and safety of standard induction treatment for AIH in the
elderly. Available evidence is insufficient to draw any conclusion on the effect of
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Core tip: Autoimmune hepatitis (AIH) is a severe liver disease that affects patients
worldwide. Conventional treatment with a steroid and azathioprine is the mainstay of
treatment. Although elderly patients have a relatively high incidence of AIH, data on its
treatment in the elderly are limited. We focused on this subgroup of patients and
systematically reviewed studies testing both efficacy and safety of AIH treatments in old
patients. Available data support the use of conventional treatment, while the effect of
other drugs has only been tested in small case series.
Citation: Durazzo M, Lupi G, Scandella M, Ferro A, Gruden G. Autoimmune hepatitis
treatment in the elderly: A systematic review. World J Gastroenterol 2019; 25(22): 0-0
URL: https://www.wjgnet.com/1007-9327/full/v25/i22/0.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i22.0000
INTRODUCTION
Autoimmune hepatitis  (AIH) is a chronic inflammatory liver disease,  potentially
leading to liver cirrhosis and hepatic failure. AIH has a variety of clinical presentation
patterns,  ranging from asymptomatic  course to acute severe liver  disease[1].  It  is
characterized by the  presence  of  interface  hepatitis  on histological  examination,
elevated  aminotransferases,  hyper-gammaglobulinemia,  and  circulating  auto-
antibodies,  such as  antinuclear  antibodies,  smooth  muscle  autoantibodies,  liver
kidney microsomial antibodies type 1, and liver cytosol specific antibody type 1. AIH
of type 1 is the most frequent subtype (90%), while AIH of type 2 is relatively rare
(10%) and occurs mainly in childhood.
A  diagnostic  scoring  system  was  developed  in  1993  by  the  International
Autoimmune Hepatitis Group (IAIHG) and revised in 1999[2,3]. A simplified scoring
system based on autoantibody titres, serum IgG levels, liver histology, and exclusion
of viral hepatitis was proposed in 2008 to ease clinical application[4]. AIH is relatively
rare with a prevalence ranging from 16 to 18 cases per 100000 inhabitants in Europe.
However, prevalence is higher in some population groups, as Alaska natives (42 cases
per 100000 inhabitants)[5]. Although initially thought to be particularly prevalent in
young women and children,  the disease can affect  all  age groups and in the last
decade several studies reported a relatively high incidence in the elderly[6,7].
Untreated AIH has a poor prognosis; however, immunosuppressive therapy shows
a high response rate and significantly improves prognosis[8]. Therapy with a steroid,
with or  without  azathioprine (AZA),  is  the  mainstay of  treatment,  but  the  most
effective and safe therapy in elderly patients remains undetermined as old people are
often excluded from clinical trials[9]. Moreover, both comorbidities and polypharmacy
make treatment choice very challenging in this age group. To clarify the efficacy of
AIH treatments specifically in the elderly, we performed a systematic review.
MATERIALS AND METHODS
The  study  was  carried  out  according  to  the  Preferred  Items  for  Reporting  of
Systematic Reviews and Meta-Analyses (PRISMA) guidelines[10]. The study protocol
was not registered.
Literature search strategy
We searched electronic databases (PubMed National Library of Medicine, EMBASE,
and Cochrane Library) to identify all  published studies on AIH treatment in the
elderly up to 20th of February 2019. The research terms (keywords, medical subject
headings,  free-terms) “autoimmune hepatitis/therapy”, “autoimmune hepatitis/
treatment”,  ‘‘elderly”,  “80 and over”,  “older”,  “aged” were used in combination
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(AND or OR operators) (Appendix 1). Reference lists were also screened to identify
additional relevant studies.  The search strategy was limited to English language
publications, while no timeline restriction was used.
We included both randomized and non-randomized studies, whereas case-reports,
case series, and letters to the Editor were excluded. Eligible studies had to assess the
effect of induction treatment of newly diagnosed AIH in either elderly patients or a
well-defined subgroup of  old patients  (threshold:  ≥  60  years  of  age).  Studies  on
elderly patients with overlap syndromes, primary biliary cirrhosis, primary sclerosing
cholangitis, chronic viral hepatitis, and drug-induced AIH were excluded.
Study selection
Three review authors independently screened titles and abstracts of eligible studies.
Disagreements were resolved through consensus by discussion. Full  text of each
study  was  then  read  and  critically  assessed  by  two  review  authors,  who  in-
dependently agreed on selection. A third review author resolved discrepancies.
Risk of bias assessment
All selected studies were non-randomized studies of interventions; therefore, we
assessed  study  quality  using  the  Risk  of  Bias  In  Non-Randomized  Studies  of
Interventions (ROBINS-I). This is a new tool for evaluating the risk of bias in estimates
of  the  comparative  effectiveness  of  interventions  from studies  that  did  not  use
randomization to allocate units to comparison groups. The tool includes seven bias
domains: three pre-intervention domains (confounding, selection of participants into
the  study,  classification  of  interventions)  and  four  post-intervention  domains
(deviations from intended interventions, missing data, measurement of outcomes, and
selection of  reported results)[11].  Two review authors  (G.L.,  M.S.)  independently
assessed the risk of bias across the seven domains for each included study and a third
review author (A.F.) acted as an arbitrator (Table 1). We excluded all the studies that
were at critical risk of bias in at least one domain.
Data collection
We extracted the following data from included studies: (1) Characteristics of study
participants (age, AIH type);  (2) Type of intervention [steroid, steroid plus AZA,
steroid plus mycophenolate mofetil (MMF), ursodeoxycholic acid (UDCA), and other
treatments] in the elderly compared to younger subjects; and (3) Type of outcomes
(both partial and complete remission, relapses, treatment failure, side effects/allergy).
For each study, data on first author surname, publication year, country of the first
author, study design, total sample size,  number of elderly patients enrolled, and
follow-up duration were also collected. We used the definition of remission given by
the Authors in the paper and we did not request study data where they were missing
from the articles.
RESULTS
Flow and characteristics of included studies
A PRISMA flow diagram of study selection is shown in Figure 1. Database search
retrieved  1736  references.  After  exclusion  of  407  duplicates,  1329  records  were
screened. Primary selection by title and abstract assessment led to the exclusion of
further 1214 articles. Among the remaining 115 papers, 100 studies were excluded
after full-text reading (e.g., case series and case reports, posters, insufficient number of
elderly  patients  in  the  sample,  no  sub-analysis  in  the  elderly  subgroup,  studies
assessing  clinical  presentation,  prevalence,  and economic  issues  in  elderly  AIH
patients rather than therapy, AIH in pediatric population). Out of the 15 remaining
studies, eight were excluded for critical risk of bias as assessed by ROBINS-I[12-19].
Study characteristics
Characteristics of the seven included studies are summarised in Table 2[6,9,20-24]. They
were comparative cohort studies, which were performed in seven different countries
(North America, Europe and Asia) and published between 2001 and 2017. A total of
789  patients  (640  F,  149  M)  with  new-onset  AIH  were  studied.  The  clinical
presentation was heterogeneous with both acute and chronic onset.  Among AIH
patients, 239 subjects (203 F, 36 M) were elders (≥ 60 years of age)[6,9,20-24].  Because
different age threshold (≥ 60, ≥ 65, ≥ 70) were used to define elderly patients in the
seven studies, the age range also differ in the comparator group. Moreover, three
studied  included  in  the  comparator  group  only  patients  with  pre-defined  age
threshold (≤ 30, ≤ 32, and ≤ 50 years of age, respectively)[6,9,22]. Diagnostic criteria for
AIH differed in the included studies. Specifically, five studies used the revised IAIHG
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Table 1  Risk of bias assessment in the included studies according to Risk Of Bias In Non-randomised Studies of Interventions scale
Biasdomains Schram et al
[6],
2001
Granito et al[21],
2005
Al-Chalabi et
al[23], 2006
Czaja et al[9],
2006
Zhang et al[22],
2012
Zachou et al[20],
2016
Morii et al[24],
2017
Confounding Moderate Serious Moderate Moderate Serious Moderate Moderate
Selection of
participants into
study
Serious Low Low Moderate Moderate Serious Moderate
Classification of
interventions
Serious Moderate Moderate Moderate Serious Moderate Moderate
Deviation from
intended
interventions
No information Low No information No information No information Low Moderate
Missing data Moderate Moderate Moderate Serious Serious Serious Serious
Measurement of
outcomes
Low Moderate Moderate Moderate Moderate Moderate Moderate
Selection of the
reported results
Moderate Moderate Moderate Moderate Moderate Serious Moderate
Overall Serious Serious Moderate Serious Serious Serious Serious
criteria, one study the simplified IAIHG criteria[20], and the study by Zhang et al[22]
both diagnostic scoring systems.
Studies differed for types of treatments and drug dosages (Table 3). However, in all
studies except one, elderly patients were treated with a steroid either alone or in
combination with AZA (170 out of 194 patients)[6,9,21-24]. The study by Zachou et al[20]
assessed the performance of an alternative first-line treatment with prednisolone and
MMF. Moreover, the study by Morii et al[24] also included a sub-study on the potential
benefit of UDCA treatment in 13 elderly AIH patients with chronic disease onset.
Fifty-nine patients  were excluded from the final  analysis  because they were not
eligible for immunosuppressive treatment (27 patients)[20], they did not satisfy the
criteria for treatment or received experimental therapies (26 patients)[9], or they did
not receive any treatment (6 patients)[6,21,22]. Follow-up duration varied widely from
two months to 33 years.
Effects of treatment
Definitions of remission, treatment failure, and relapse are reported in Table 4. In the
elderly, standard therapy with a steroid either alone or in combination with AZA
induced remission in 119 out of 151 patients. In the studies by Granito et al[21] and Al-
Chalabi et al[23], the remission rate was of 90% and 95%, respectively. The likelihood of
remission  in  the  elderly  was  similar  to  that  observed  in  the  other  age  groups.
Treatment failure occurred less often in old compared to younger patients (Czaja et
al[9]:  9.1% vs  28.2%, P  = 0.041; Zhang et al[22]:  5% vs  24%, P  = 0.03). In the study by
Zachou et  al[20],  treatment with a steroid combined with MMF achieved a greater
complete response rate than standard treatment with a steroid combined with AZA,
independently of age.
The response rate to therapy was similar in the Czaja et al[9] and the Zhang et al[22]
studies despite different ethnicity of the studied populations (Caucasian vs Chinese
patients).  However, a higher rate of response was seen in the Caucasian patients
enrolled  in  the  Schramm et  al[6]  study.  No information  on  patient  ethnicity  was
provided by the other studies.
Only a few studies reported the relapse rate during steroid taper or soon after
discontinuation. Relapse rate was higher in younger compared to elderly patients in
the study by Al-Chalabi et al[23] (70% vs 42%, P = 0.002). A similar trend was observed
in the studies by Granito et al[21] and Schramm et al[6], though it did not reach statistical
significance. On the contrary, no difference in relapse rate between old and younger
patients was observed in the study by Czaja et al[9]. In patients treated with UDCA,
remission was observed in 17 out of 34 patients (50%), but data stratified for age were
not reported[24].
Other outcomes
Treatment side effects were described in four studies. In the paper by Granito et al[21],
the elderly group did not report any side effect, while steroid-related adverse effects,
such as osteoporosis, diabetes, and myopathy, occurred in the comparator group. In
the study by Al-Chalabi et al[23], side effect frequency did not differ in the two age
groups, except for Cushingoid facies and psychotic episodes that were reported in
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Figure 1
Figure 1  Flow chart of the search strategy.
elderly group only (2 cases). Other side effects in elderly patients were osteoporosis
(12%), hypertension (7%), type 2 diabetes (2%), and AZA-induced cytopenia (5%)[23].
In the paper by Schramm et  al[6],  five patients  discontinued treatment with AZA
because of gastrointestinal undesirable events, cholestasis, and skin rash. Moreover,
one  elderly  patient  had a  varicella  zoster  infection  and another  one  pulmonary
tuberculosis reactivation[6]. In the study assessing the effect of MMF, treatment was
well  tolerated  in  all  age  groups,  though  few  patients  had  septicaemia,  mild
gastrointestinal symptoms, or cytopenia[20].
DISCUSSION
AIH, a chronic inflammatory liver disease, may present at any age. However, there is
relatively  little  information  on  AIH  clinical  features  and  management  in  older
patients. In 2013, Chen et al[25] published a systematic review on AIH treatment in the
elderly, supporting the use of a steroid combined with AZA to achieve long-term
remission.  Since  then,  alternative  treatments,  including  6-mercaptopurine,
everolimus, tacrolimus, and methotrexate, were successfully used as first-line AIH
therapy in adult patients[26]. However, efficacy was not tested in randomized clinical
trials and available data in elderly patients are scarce.
Our systematic review results show that therapy with a steroid either alone or with
AZA is still the most frequently used treatment in elderly patients. This therapeutic
strategy is highly effective in achieving remission. Moreover, treatment failure occurs
less frequently in the elderly than in younger patients and elderly people are more
likely to maintain remission[6,9,21-24].
Treatments were well tolerated; however, included studies did not systematically
report  adverse effects.  Notably,  none of  studies reported the use of  calcium and
vitamin D supplementations to prevent osteoporosis, though osteoporosis is one of
the most common adverse effect in elderly people treated with steroids. Similarly, a
multicentre study reported that only AIH patients with established osteoporosis were
treated with bisphosphonates, calcium, and vitamin D supplements[27].
In  elderly  patients,  other  drugs  can  be  used  instead  of  standard  therapy,
particularly in subjects who are likely to experience relevant steroid- and AZA-related
side effects. Nevertheless, the effect of novel treatments for AIH in the elderly was
only described in case reports and small case series[28-33], which were not included in
this systematic review. Among the included studies, only the paper of Zachou et al[20]
tested an alternative first-line therapy with MMF.
Our systematic review has several limitations. The sample size of included studied
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Table 2  Characteristics of included studies
Author(year) Methods
No. of
patients (F:M) Diagnostic
criteria Country Interventions Median FU Outcomes Side effectsElderly:Youn-
ger
Schramm et
al[6], 2001
Comparative
Cohort Study
40 (32:8) IAIHG (1999) Germany -P alone 4-164 mo CR, relapse, all
causes and
liver-related
death
GI symptoms,
cholestasis, skin
rush (AZA). VZ
infection,
pulmonary TB
reactivation
-P + AZA (40 mo in
elderly group)20 (≥ 65 yr,
50%):20
-No treatment
Granito et
al[21], 2005
Comparative
Cohort Study
76 (64:12) IAIHG (1999) Italy -M alone 1-16 yr (5 yr) in
the elderly
CR, relapse,
death
None in elderly
group20 (≥ 65 yr,
26%):56
-M + AZA
-No treatment
Al-Chalabi et
al[23], 2006
Comparative
Cohort Study
164 (128:36) IAIHG (1999) UK -P alone 1-28 yr (9 yr) CR, PR, TF,
relapse,
deaths/OLT
Cushingoid
faces,
osteoporosis,
T2DM,
hypertension,
psychoses.
Cytopenia
(AZA)
-P + AZA
43 (≥ 60 yr,
26%):121
-(P + Cyclo
and P + D-P in
young only)
Czaja et al[9],
2006
Comparative
Cohort Study
205 (175:30) IAIHG (1999) USA -Pp alone (77 mo) Remission, SR,
TF, relapse,
death or OLT
Not reported
-Pp + AZA
47 (≥ 60 yr,
23%):158
-P + AZA
-No treatment
Zhang et al[22],
2012
Comparative
Cohort Study
75 (71:4) IAIHG (1999) China -P alone 6 mo-8 yr Remission, SR,
TF, relapse,
death
Not reported
36 (≥ 60 yr,
48%):39
+ IAIHG (2008)
Zachou et
al[20], 2016
Comparative
Cohort Study
158 (114:44) IAIHG (2008) Greece -P + MMF 3-168 mo (72) in
MMF group
CR, PR, TF,
relapse, liver-
related death,
progression
during FU,
OLT
Sepsis, airway
infections, VZ,
mild GI
symptoms,
cytopenia
(MMF)
45 (> 60 yr,
28%):113
-P alone
-P + AZA
Morii et al[24],
2017
Comparative
Cohort Study
71 (56:15) IAIHG (1999) Japan -Pp alone 2-69 mo (31 mo) Remission,
relapses
Not reported
28 (≥ 70 yr,
39%):43
-UDCA
IAIHG:  International  Autoimmune  Hepatitis  Group;  P:  Prednisolone;  Pp:  Prednisone;  AZA:  Azathioprine;  M:  Methylprednisolone;  Cyclo:
Cyclophosphamide; D-P: D-Penicillamine; MMF: Mycophenolate Mofetil; UDCA: Ursodeoxycholic acid; CR: Complete Remission; PR: Partial remission;
SR: Sustained remission; TF: Treatment failure; OLT: Orthotopic liver transplantation; GI: Gastro-Intestinal; VZ: Varicella zoster; T2DM: Type 2 diabetes
mellitus; TB: Tubercolosis.
was small and the study quality relatively low. In addition, studies were hetero-
geneous in terms of AIH diagnostic criteria, outcome definition, cluster classification,
disease severity, and comorbidities. Finally, we have no data on elderly patients of
different age subgroups.
In conclusion, there is insufficient evidence to draw any conclusion regarding both
efficacy and safety of  novel  AIH treatment  approaches in  the elderly.  However,
present data confirm that conventional AIH treatment is effective in elderly patients
and that efficacy may be even greater than in younger subjects.  Moreover,  early
treatment  is  recommended to  achieve  remission  and  avoid  progression.  Larger
clinical studies are required to establish whether elderly patients may benefit from
other therapeutic approaches.
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Table 3  Treatment regimens
Author (year) Treatments
Schramm et al[6], 2001 P 1 mg/kg/die
P 1 mg/kg/die + AZA 1-1.5 mg/kg/die
No treatment
Granito et al[21], 2005 M 1 mg/kg/die
M 30 mg/die + AZA 50 mg/die
No treatment
Al-Chalabi et al[23], 2006 P 20-40 mg/die
P 20-40 mg/die + AZA (1 mg/kg/die)
P 20-40 mg/die + Cyclo (only in the younger group)
P 20-40 mg/die + D-P (only in the younger group)
Czaja et al[9], 2006 Pp (doses not specified)
Pp + AZA (doses not specified)
Investigational therapies (drugs not specified)
No Treatment
Zhang et al[22], 2012 P (doses not specified)
P + AZA (doses not specified)
No treatment
Zachou et al[20], 2016 P 0,5-1 mg/kg/die + MMF 1.5-2g/die
P 0,5-1 mg/kg/die
P 0.5-1 mg/kg/die + AZA 1.5-2 mg/kg/die
Morii et al[24], 2017 Pp 30-40 mg/die
UDCA (dose not specified)
P: Prednisolone; Pp: Prednisone; AZA: Azathioprine; M: Methylprednisolone; Cyclo: Cyclophosphamide; D-P: D-Penicillamine; MMF: Mycophenolate
Mofetil; UDCA: Ursodeoxycholic acid.
Table 4  Outcome definitions
Author (year) Remission Treatment failure Relapse
Schramm et al[6], 2001 IAIHG revised criteria (1999) - IAIHG revised criteria (1999)
Granito et al[21], 2005 IAIHG revised criteria (1999) - IAIHG revised criteria (1999)
Al-Chalabi et al[23], 2006 IAIHG revised criteria (1999) IAIHG original criteria (1993) IAIHG revised criteria (1999)
PR: IAIHG original criteria (1993)
Czaja et al[9], 2006 Symptoms: Absent Worsening of clinical, laboratory
and/or histological alterations
despite compliance to therapy
Symptom recurrence and increased
serum AST level (> three-fold the
ULN) after drug withdrawal
AST level: Normal or near normal (<
two-fold the UNL)
Histology: Minimal/no inflammation
SR:
Symptoms: Absent
Serum AST levels: Normal or below
the relapse threshold
after drug withdrawal
Zhang et al[22], 2012 Symptoms: Absent Worsening of clinical, laboratory
and/or histological alterations
despite compliance to therapy
Symptom recurrence and increased
serum AST level (> three-fold the
ULN) after drug withdrawal
AST levels: Normal or near normal (<
two-fold the UNL)
Histology: Minimal or no
inflammation.
SR:
Symptoms: Absent
AST levels: Normal or below the
relapse threshold after drug
withdrawal
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Zachou et al[20], 2016 CR: Persistently elevated AST and ALT (>
three-fold the UNL) and/or increased
IgG despite intensive
immunosuppression and compliance
to therapy
Rise in AST and ALT levels (> three-
fold the UNL) and/or increased IgG
(> 2000 mg/dL) during therapy with
or without symptom recurrence after
initial CR
Symptoms: Improved
AST, ALT, IgG levels: normal
Histology: Minimal/no inflammation
PR:
ALT or AST levels: Decreased (< two-
fold ULN) without achieving
complete normalization and inability
to withdraw or taper prednisolone
Morii et al[24], 2017 Normal serum ALT and IgG levels - Re-exacerbation not explicitly
defined
IAIHG: International Autoimmune Hepatitis Group; ALT: Alanine transaminase; AST: Aspartate transaminases; ULN: Upper limit of normal; IgG:
Immunoglobulin G; CR: Complete remission; PR: Partial remission; SR: Sustained remission.
ARTICLE HIGHLIGHTS
Research background
Autoimmune hepatitis (AIH) is a rare chronic inflammatory disease potentially leading to severe
liver  damage.  Untreated  AIH  has  a  poor  prognosis,  but  the  response  rate  to  fist-line
immunosuppressive therapy with a steroid either alone or in combination with azathioprine is
very high. Moreover, novel immunosuppressive drugs have been recently proposed for AIH
treatment in adult patients.
Research motivation
AIH also affects elderly patients; however, only a few intervention studies were performed in
old patients. Whether standard treatment with a steroid, with or without azathioprine, is the best
therapeutic strategy in the elderly is unclear.
Research objectives
To assess current evidence on AIH therapy in the elderly, we systematically reviewed studies
testing both efficacy and safety of first-line pharmacotherapy for AIH in the elderly.
Research methods
Electronic databases (PubMed National Library of Medicine, EMBASE, Cochrane Library) were
searched to identify studies on AIH treatment in the elderly (≥ 60 years of age). Following study
selection, eligible studies underwent risk of bias assessment.  Data on study characteristics,
interventions, and outcomes were then extracted. The work was carried out according to the
PRISMA Guidelines.
Research results
Seven cohort studies,  enrolling 789 AIH patients,  were included. Elderly patients were 239
(30.3%). Six studies reported data on the efficacy of convention treatment with a steroid (alone or
in  combination  with  azathioprine)  in  elderly  and  younger  AIH  patients.  Only  one  study
compared the effect of another drug (mycophenolate mofetil). Overall remission rate was high
and comparable in elderly and younger patients. Notably, both failure of treatment and relapses
occurred less frequently in elderly patients. Adverse effects were rare in both groups. The quality
of the evidence was low and the heterogeneity elevated among included studies.
Research conclusions
Our results confirm the efficacy and safety of standard treatment with a steroid and azathioprine
for  AIH  in  the  elderly.  Data  on  other  type  of  treatments  were  insufficient  to  draw  final
conclusion.
Research perspectives
Available data on pharmacotherapy for AIH in the elderly are very limited and the effect of
novel drugs poorly known. Moreover, results were obtained in small non-randomised studies
that were heterogeneous for patient clinical characteristics, outcome assessment, and follow-up
duration. Therefore, well-designed randomized clinical trials, comparing efficacy and safety of
currently available first-line drugs for AIH in the elders, are needed. In addition, further studies
are required to establish effectiveness of second-line treatments for elderly patients resistant to
conventional therapy.
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